Browse News
Filter News
Found 11,774 articles
-
In the second half of the calendar year, the biopharma industry continues to ascend in mergers and acquisitions, new drug approvals and big investments, indicate market confidence and growth.
-
Kymera has raised money through sale of more than 2,769,000 shares of common stock to help support the company's ongoing clinical and preclinical programs.
-
Cases of monkeypox infections reported in the latest viral outbreak have surpassed 14,000 in the U.S., according to the CDC. Some scientists believe the outbreak was predictable.
-
This week's Movers & Shakers include Arvinas, Inspire and Cambridge Isotope Laboratories all announcing new VP roles, and several others tap new C-suite executives.
-
Human Vaccines Market: Growing Preference for Outsourcing of Vaccine Manufacturing to Drive the Market
8/19/2022
Wilmington, Delaware, United States, Transparency Market Research Inc. – The human vaccines market is anticipated to experience significant growth avenues in the upcoming years.
-
Artemisinin Combination Therapy Market Insights and Emerging Trends by 2027
8/19/2022
The conventional low-priced mainstay drugs for the treatment of malaria, sulphadoxine-pyrimethamine and chloroquine, are witnessing a decline in sales, as they are becoming comparatively ineffective.
-
Cases of monkeypox are growing at an alarming rate and Bavarian Nordic, the company that owns one of the two approved vaccines, may no longer be able to keep up.
-
Odylia Therapeutics Announces Appointment of Two New Members to Board of Directors
8/18/2022
Odylia Therapeutics today announced the appointments of Sharon M. Walker , Ph.D., J.D., and Brian Fenton to its Board of Directors.
-
Alnylam to Present Data from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at the 18th International Symposium on Amyloidosis
8/18/2022
Alnylam to Present Data from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at the 18th International Symposium on Amyloidosis.
-
Rentschler Biopharma appoints Mark Caswell as Vice President, Site Head for US Facility
8/18/2022
Rentschler Biopharma, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, today announced the appointment of Mark Caswell as Vice President, Site Head.
-
All other ongoing and pending studies of Sanofi's amcenestrant, including the early-stage breast cancer trial AMEERA-6, will also be discontinued.
-
Atomwise inked a strategic research-and-development deal with Sanofi to use the AtomNet platform to identify and research up to five drug targets.
-
Innovent Announces First Subject Dosed in Phase 1 Study of IBI311 (Anti-IGF-1R Monoclonal Antibody)
8/17/2022
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, announces that the first healthy volunteer has been successfully dosed in the Phase 1 study of IBI311.
-
Magenta Therapeutics Appoints Michael Vasconcelles, M.D. to the Board of Directors
8/17/2022
Magenta Therapeutics today announced that it has appointed Michael Vasconcelles, M.D. to its board of directors.
-
Exscientia Business Update for Second Quarter and First Half 2022
8/17/2022
Recent developments in the Company’s pipeline, collaborations, and operations, as well as financial results for the second quarter and first half 2022, are summarised below.
-
Press Release: Sanofi provides update on amcenestrant clinical development program
8/17/2022
Sanofi is discontinuing the global clinical development program of amcenestrant, an investigational oral selective estrogen receptor degrader.
-
Atomwise Signs Strategic Multi-Target Research Collaboration with Sanofi for AI-Powered Drug Discovery
8/17/2022
Atomwise, a leader in using artificial intelligence (AI) for small molecule drug discovery, today announced that it has established a strategic and exclusive research collaboration with Sanofi that will leverage its AtomNet® platform for computational discovery and research of up to five drug targets.
-
Biologics Market Size Worth USD 567.96 Billion in 2028
8/17/2022
The global biologics market is projected to reach USD 567.96 Billion in 2028 at a steady revenue CAGR of 8.4% over the forecast period, according to latest analysis by Emergen Research.
-
Pruritus Therapeutics Market Size Worth USD 19.98 Billion By 2028
8/17/2022
According to the current analysis of Reports and Data, the global Pruritus Therapeutics market was valued at USD 12.40 Billiion in 2020 and is expected to reach USD 19.98 Billion by year 2028, at a CAGR of 6.23 percent.
-
Anxiety Disorder and Depression Treatment Market Is Expected To Reach USD 19.53 Billion By 2028
8/17/2022
The Global Anxiety Disorder and Depression Treatment Market size is forecast to reach USD 19.53 Billion by 2028, registering a CAGR of 2.4% over the forecast period, according to a new report by Reports and Data.